


## **Supplementary Materials**

### **Clerodane diterpenoids from an edible plant *Justicia insularis*: discovery, cytotoxicity, and apoptosis induction in human ovarian cancer cells**

Idowu E. Fadayomi<sup>1</sup>, Okiemute R. Johnson-Ajinwo<sup>1</sup>, Elisabete Pires<sup>2</sup>, James McCullagh<sup>2</sup>, Tim D. W. Claridge<sup>2</sup>, Nicholas R. Forsyth<sup>1</sup>, and Wen-Wu Li<sup>1\*</sup>


<sup>1</sup>School of Pharmacy and Bioengineering, Keele University, Stoke on Trent, ST4 7QB, UK

<sup>2</sup>Department of Chemistry, University of Oxford, Mansfield Road, Oxford, OX1 3TA, UK



**Figure S1.** Scheme showing the extraction, bioassay-guided purification, and identification of cytotoxic compound **1** and **2** from *J. insularis*.

**A)**



**B)**






Figure S2: Mean concentration-response curve of the active extract of *J. insularis* (DCM/MeOH) in OVCAR 4 (A) and OVCAR 8 (B) ovarian cancer cell lines, showing potent cytotoxic activity of the organic extracts.

**A)**




**B)**




**Figure S3.** Analytical HPLC chromatograms of purified active compounds of *J. insularis*. (A) Compound 1 has a single peak at retention time 22.749 min indicating a purity of 97% and (B) compound 2 shows a major peak at retention time 23.134 min (purity 85%) and presence of a minor peak.


**A)**



**B)**



**Figure S4:** LC-HRMS chromatogram (A) and negative ESI-MS spectrum (B) of isolated compound **1** showing the HRMS of the major peak at a retention time of 12.87 min. The found high resolution mass of  $m/z$  at 317.2123 [ $M-H^-$ ] was consistent with its theoretical masses of 317.2117.



**Figure S5:** GC-MS chromatogram and mass spectra of the isolated compound **1** at Rt 18.45 min and two thermal degradation products of **1a** and **1b** under high temperature in the oven of GC-MS. Compound **1a** shows similar fragmentation ions as those of **1** but with an intensive ion *m/z* at 285.1 instead of 275.1 for **1**. Compound **1** and **1a** are unlikely their isomers due to the presence of this significant different fragmentation ion. Compound **1b** shows a molecule ion *m/z* at 300 due to loss of a water molecule instead of an ion at 318.2 for **1**.





Figure S6: NMR data analysis of *Justicia insularis* of the purified compound 1 and hexane fraction in  $\text{CDCl}_3$ : (A)  $^1\text{H}$ -NMR (500 MHz), (B)  $^{13}\text{C}$ -NMR (125 MHz) spectrum, (C)  $^{13}\text{C}$ -NMR (100 MHz) spectrum (range of 110-180 ppm) of hexane fraction containing 1 before silica gel chromatography and HPLC. The assignment of each peak is indicated in Table S3. The ratio of the  $16\alpha$  and  $16\beta$  form of compound 1 is determined to be 1:1 by calculating the ratio of the integration value of the carbon peak at 116.94 ppm (C-14,  $16\alpha$  form) to that of the peak at 116.97 ppm (C-14,  $16\beta$  form). The epimers of compound 1 were present in the hexane fraction before purification process which may cause isomerisation, so epimers of compound 1 are natural products in *J. insularis*.





Figure S7: LC-MS chromatogram (**A**) and negative ESI-MS spectrum (**B**) of isolated compound 2 at retention time of 13.45 min. The found masses of  $m/z$  at 317.2127 $[M-H]^-$ , and 635.4302 [2M-H] $^-$  were consistent with their theoretical masses of 317.2117 and 635.4312, respectively.

**A)**



**B)**




Figure S8: NMR data analysis of *Justicia insularis* purified compound 2 in  $\text{CDCl}_3$ : (A)  $^1\text{H}$ -NMR and (B)  $^{13}\text{C}$ -NMR. The assignment of each peak is indicated in Table S3.

Table S1: The results of the growth inhibitory activities of *J. insularis* extracts and fractions on ovarian cancer OVCAR-4 and OVCAR-8 cell lines.

Extracts, Fractions and Pure compounds	Abbrev.	IC <sub>50</sub> on OVCAR-4 ( $\mu$ g/mL)	IC <sub>50</sub> on OVCAR-8 ( $\mu$ g/mL)
Dichloromethane /methanol Extract	DCM/MeOH	19.2 $\pm$ 0.5	10.7 $\pm$ 0.6
Aqueous Extract	Aq Ext	> 150.0	99.8 $\pm$ 0.3
<i>n</i> -Hexane	<i>n</i> -Hex JI	19.5 $\pm$ 1.0	6.1 $\pm$ 1.8
Ethyl acetate	EA	25.7 $\pm$ 1.5	7.5 $\pm$ 1.7
<i>n</i> -Butanol	<i>n</i> -But	188.4 $\pm$ 4.6	101.7 $\pm$ 2.2
Aqueous fraction	Aq	80.0 $\pm$ 0.8	71.5 $\pm$ 14.9

Table S2: The growth inhibitory activities of EA fractions and EA4 sub-fractions of *J. insularis* on OVCAR-4 ovarian cancer cell line.

J. <i>insularis</i>	IC <sub>50</sub> value ( $\mu$ g/mL) on OVCAR-4 cell	EA4 Sub-fractions of <i>J. insularis</i>		IC <sub>50</sub> value ( $\mu$ g/mL) on OVCAR-4 Cell	
		line			
		EA1	EA4-1		
EA2	5.9 $\pm$ 0.1		EA4-2	9.1 $\pm$ 2.6	
EA3	6.7 $\pm$ 0.1		EA4-3	5.3 $\pm$ 1.1	
EA4	4.1 $\pm$ 0.4	→ EA4-4		3.0 $\pm$ 0.4	
EA5	6.2 $\pm$ 0.4		EA4-5	9.4 $\pm$ 0.5	
EA6	5.7 $\pm$ 0.8	→ EA4-6		2.6 $\pm$ 0.2	
EA7	12.0 $\pm$ 0.3		EA4-7	10.3 $\pm$ 2.4	
EA8	11.5 $\pm$ 0.3		EA4-8	4.8 $\pm$ 0.9	
EA9	43.7 $\pm$ 1.4		EA4-9	5.8 $\pm$ 0.9	
EA10	68.4 $\pm$ 3.3		EA4-10	7.2 $\pm$ 0.8	
			EA4-11	14.2 $\pm$ 2.3	

Table S3:  $^1\text{H}$  (500 MHz) and  $^{13}\text{C}$ -NMR (125 MHz) assignments of isolated compound 1 and 2 ( $\text{CDCl}_3$ ).

H	$^1\text{H-NMR}$		C	$^{13}\text{C-NMR}$	
	1( $16\alpha + 16\beta$ )	2		1( $16\alpha + 16\beta$ )	2
1	1.48-1.55 (overlapped, m, 2H)	1.79 (dt, 12.8, 3.3Hz 1H); 1.46 (overlapped, 1H)	1	18.0	18.1
2	2.03 (overlapped, 2H)	2.10 (m, 2H)	2	26.79, 26.80	26.8
3	5.21 (brs, 1H)	5.24 (brs, 1H)	3	120.36, 120.43	120.7
			4	144.33, 144.39	144.3
			5	38.2	38.2
6	1.20 (td, 13.0, 4.5 Hz, 1H), 1.73 (td, 13.0, 5.0 Hz, 1H)	1.22 (m, 1H), 1.74 (td, 12.5, 3.5 Hz, 1H)	6	36.7	36.8
7	1.46 (overlapped, 2H)	1.50 (overlapped, 2H)	7	27.37	27.6
8	1.47 (m, 1H)	1.62 (overlapped, 1H)	8	36.36, 36.32	36.3
			9	38.66, 38.70	39.4
10	1.35 (dd, 12, 2.0 Hz, 1H)	1.43 (overlapped, 1H)	10	46.5	46.6
11	1.73 (dd, 14.2, 3.3 Hz, 1H); 1.68 (ddd, 14.2, 9.1, 4.9 Hz, 1H)	1.21, 1.30 (overlapped, 2H)	11	34.8	37.0
12	16 $\alpha$ form: 2.40 (ddd, 14.2, 5.0, 1.4 Hz, H), 2.25 (ddd, 14.2, 4.3, 1.4 Hz, 1H) 16 $\beta$ form: 2.32 (ddd, 14.1, 5.0, 1.3 Hz, 1H); 2.15 (ddd, 14.1, 4.7, 1.7 Hz, 1H)	2.57 (ddd, 11.0, 5.2, 1.6 Hz, 1H); 2.30 (ddd, 11.0, 4.4, 3.7 Hz, 1H)	12	21.35, 21.38	19.2
14	5.85 (s, 1H)	6.49 (s, 1H)	13	170.72, 170.76	157.7
			14	116.94, 116.97	133.5
16	6.03 (brs, 1H)	9.57 (s, 1H)	15	171.7	169.3
17	16 $\alpha$ form: 0.83 (d, 5.5 Hz, 3H); 16 $\beta$ form: 0.82 (d, 5.8 Hz, 3H)	0.87 (d, 7.3 Hz, 3H)	16	99.14, 99.16	194.3
			17	16.00	15.9
18	16 $\alpha$ form: 1.61 (d, 3H); 16 $\beta$ form: 1.60 (s, 3H)	1.61 (s, 3H)	18	18.23	18.0
19	1.03 (s, 3H)	1.02 (s, 3H)	19	19.9	19.9
20	0.79 (s, 3H)	0.71 (s, 3H)	20	18.2	18.1

Table S4. Molecular descriptors and drug-likeness of compounds 1 and 2 in *J. insularis* calculated by SwissADME web tool.

Compound	Formula	Molecular weight	Num. rotatable bonds	Num. H-bond acceptors	Num. H-bond donors	Molar Refractivity	Topological Polar Surface Area (TPSA)	Log Po/w (iLOG P)	Drug-likeness (Lipinski rule)
<b>1</b>	C <sub>20</sub> H <sub>30</sub> O <sub>3</sub>	318.45 g/mol	3	3	1	92.89	46.53 Å <sup>2</sup>	3.10	Yes
<b>2</b>	C <sub>20</sub> H <sub>30</sub> O <sub>3</sub>	318.45 g/mol	5	3	1	94.53	54.37 Å <sup>2</sup>	2.79	Yes




Figure S9 Distribution of predicted targets molecules of compound 1 by the SwissADME web tool (Table S5).




Figure S10. Distribution of predicted targets molecules of compound 2 by the SwissADME web tool (Table S6).

Table S5. Predicted protein targets of compound 1 by SwissTargetPrediction web tool  
<http://www.swisstargetprediction.ch>.

Target	Common name	Uniprot ID	ChEMBL ID	Target Class	Probability*	Known actives (3D/2D)
Ribosomal protein S6 kinase alpha 5	RPS6K A5	O755 82	CHEMBL4237	Kinase	0.13	2 / 4
Potassium-transporting ATPase alpha chain 2	ATP12 A	P547 07	CHEMBL2933	Primary active transporter	0.11	0 / 9
Androgen Receptor		P102 AR	CHEMBL1871	Nuclear receptor	0.10	140 / 64
Dual specificity phosphatase Cdc25A		P303 CDC25 A	CHEMBL3775	Phosphatase	0.10	4 / 15
Progesterone receptor		P115 PGR CYP19	CHEMBL208	Nuclear receptor	0.10	121 / 41
Cytochrome P450 19A1	A1	P115 11	CHEMBL1978	Cytochrome P450	0.10	224 / 73
Dual specificity phosphatase Cdc25B	B	P303 CDC25 B	CHEMBL4804	Phosphatase	0.10	4 / 12
Phospholipase A2 group 1B	PLA2G 1B	P040 54	CHEMBL4426	Enzyme	0.10	0 / 4
Taste receptor type 2 member 31	TAS2R 31	P595 38	CHEMBL2034804	Taste family G protein-coupled receptor	0.10	0 / 1
Glucocorticoid receptor	NR3C1	P041 50	CHEMBL2034	Nuclear receptor	0.10	80 / 12
Testis-specific androgen-binding protein		P042 SHBG	CHEMBL3305	Secreted protein	0.10	46 / 17
Dual specificity phosphatase Cdc25C	CDC25 C	P303 07	CHEMBL2378	Phosphatase	0.10	0 / 4
11-beta-hydroxysteroid dehydrogenase 2	HSD11 B2	P803 65	CHEMBL3746	Enzyme	0.10	0 / 12
Cytochrome P450 2C19	HSD11 CYP2C	P288 19	CHEMBL3622	Cytochrome P450	0.10	10 / 3
11-beta-hydroxysteroid dehydrogenase 1	HSD11 B1	P288 45	CHEMBL4235	Enzyme	0.10	126 / 22

Table 6. Predicted protein targets of compound 2 by SwissTargetPrediction web tool  
(<http://www.swisstargetprediction.ch>).

Target	Common name	Uniprot ID	ChEMBL ID	Target Class	Probabilty *	Known actives (3D/2D)
Estrogen receptor beta	ESR2	Q92731	CHE MBL2 42	Nuclear receptor	0.24	3 / 15
Steroid 5-alpha-reductase 2	SRD5A2	P31213	CHE MBL1 856	Oxidoreductase	0.20	22 / 35
Estrogen receptor alpha	ESR1	P03372	CHE MBL2 06	Nuclear receptor	0.13	6 / 14
T-cell protein-tyrosine phosphatase	PTPN2	P17706	CHE MBL3 807	Phosphatase	0.10	2 / 17
Protein-tyrosine phosphatase 1B	PTPN1	P18031	CHE MBL3 35	Phosphatase	0.10	9 / 50
11-beta-hydroxysteroid dehydrogenase 1	HSD11B1	P28845	CHE MBL4 235	Enzyme	0.10	52 / 32
Nitric oxide synthase, inducible (by homology)	NOS2	P35228	CHE MBL2 481	Enzyme	0.10	2 / 20
Protein farnesyltransferase	FNTA FNTB	P49354 P49356	CHE MBL2 09410 8	Enzyme	0.10	21 / 7
Prostaglandin E synthase	PTGES	O14684	CHE MBL5 658	Enzyme	0.10	25 / 13
DNA polymerase beta (by homology)	POLB	P06746	CHE MBL2 392	Enzyme	0.10	0 / 9
Corticosteroid binding globulin	SERPINA6	P08185	CHE MBL2 421	Secreted protein	0.10	0 / 20
Sigma opioid receptor Testis-specific androgen-binding protein	SIGMAR1	Q99720	CHE MBL2 87	Membrane receptor	0.10	0 / 3
	SHBG	P04278	CHE MBL3 305	Secreted protein	0.10	0 / 40
Pregnane X receptor	NR1I2	O75469	CHE MBL3 401	Nuclear receptor	0.10	0 / 3
Cytochrome P450 17A1	CYP17A1	P05093	CHE MBL3 522	Cytochrome P450	0.10	0 / 24
Protein kinase C eta	PRKCH	P24723	CHE MBL3 616	Kinase	0.10	0 / 1
Estradiol 17-beta-dehydrogenase 3	HSD17B3	P37058	CHE MBL4 234	Enzyme	0.10	0 / 1

Nuclear receptor subfamily 1 group I member 3 (by homology)	NR1I3	Q14994	CHE MBL5 503 CHE MBL3 775 CHE MBL4 804	Nuclear receptor	0.10	0 / 2
Dual specificity phosphatase Cdc25A	CDC25A	P30304	CHE MBL3 775	Phosphatase	0.10	5 / 13
Dual specificity phosphatase Cdc25B	CDC25B	P30305	CHE MBL4 804	Phosphatase Family A G	0.10	2 / 6
Leukotriene B4 receptor 1	LTB4R	Q15722	CHE MBL3 911 CHE	protein- coupled receptor	0.10	17 / 6
Steroid 5-alpha- reductase 1 UDP- glucuronosyltransferas e 2B7	SRD5A1	P18405	CHE MBL1 787	Oxidoreduct ase	0.10	7 / 8
UGT2B7		P16662	CHE MBL4 370	Enzyme	0.10	4 / 4
Niemann-Pick C1-like protein 1	NPC1L1	Q9UHC9	CHE MBL2 027	Other membrane protein	0.10	0 / 8
Solute carrier family 22 member 12	SLC22A12	Q96S37	CHE MBL6 120	Electrochem ical transporter	0.10	59 / 0
Aldo-keto reductase family 1 member B10	AKR1B10	O60218	CHE MBL5 983	Enzyme Fatty acid binding	0.10	13 / 6
Fatty acid-binding protein, liver (by homology)	FABP1	P07148	CHE MBL5 421	protein family	0.10	1 / 3
Cytochrome P450 19A1	CYP19A1	P11511	CHE MBL1 978	Cytochrome P450	0.10	1 / 297
Transient receptor potential cation channel subfamily A member 1	TRPA1	O75762	CHE MBL6 007	Voltage- gated ion channel	0.10	1 / 2
Type-1 angiotensin II receptor	AGTR1	P30556	CHE MBL2 27	Family A G protein- coupled receptor	0.10	47 / 0
G protein-coupled receptor 44	PTGDR2	Q9Y5Y4	CHE MBL5 071	Family A G protein- coupled receptor	0.10	632 / 0
Thromboxane-A synthase	TBXAS1	P24557	CHE MBL1 835	Cytochrome P450	0.10	150 / 0
Progesterone receptor	PGR	P06401	CHE MBL2 08	Nuclear receptor	0.10	5 / 50
11-beta-hydroxysteroid dehydrogenase 2	HSD11B2	P80365	CHE MBL3 746	Enzyme	0.10	5 / 21
MAP kinase ERK1	MAPK3	P27361	CHE MBL3 385	Kinase	0.10	0 / 1

Arachidonate 5-lipoxygenase	ALOX5	P09917	CHE MBL2 15 CHE	Oxidoreductase	0.10	31 / 21
	PSEN2 PSENEN NCSTN APH1A	P49810 Q9NZ42 Q92542 Q96BI3	MBL2 09413			
Gamma-secretase	PSEN1 APH1B	P49768 Q8WW43	5 CHE MBL2 083 CHE MBL4 360 CHE MBL2 05 CHE MBL3 242 CHE MBL3 594 CHE MBL2 35 CHE MBL4 411 CHE MBL1 825 CHE MBL1 914 CHE MBL4 822 CHE MBL2 903 CHE MBL2 39 CHE MBL2 034 CHE MBL1 808 CHE MBL1 944 CHE MBL2 17 CHE MBL3 979	Protease Fatty acid binding protein family Electrochem ical transporter Lyase Lyase Lyase Nuclear receptor Enzyme Secreted protein Hydrolase Protease Enzyme Nuclear receptor Nuclear receptor Protease Protease Family A G protein- coupled receptor receptor	0.10 0.10	7 / 0 45 / 3 19 / 0 11 / 0 7 / 0 7 / 0 144 / 16 5 / 0 0 / 6 0 / 2 0 / 2 1 / 0 94 / 11 9 / 34 181 / 0 136 / 0 1 / 0 28 / 9
Fatty acid binding protein adipocyte Monocarboxylate transporter 1 (by homology)	FABP4 SLC16A1	P15090 P53985				
Carbonic anhydrase II	CA2	P00918				
Carbonic anhydrase XII	CA12	O43570				
Carbonic anhydrase IX Peroxisome proliferator-activated receptor gamma	CA9 PPARG	Q16790 P37231				
Prostaglandin E synthase 2	PTGES2	Q9H7Z7				
TNF-alpha	TNF	P01375				
Butyrylcholinesterase	BCHE	P06276				
Beta-secretase 1	BACE1	P56817				
Arachidonate 15-lipoxygenase Peroxisome proliferator-activated receptor alpha	ALOX15 PPARA	P16050 Q07869				
Glucocorticoid receptor	NR3C1	P04150				
Angiotensin-converting enzyme	ACE	P12821				
Neprilysin	MME	P08473				
Dopamine D2 receptor Peroxisome proliferator-activated receptor delta	DRD2 PPARD	P14416 Q03181				

p53-binding protein Mdm-2	MDM2	Q00987	CHE MBL5 023	Other nuclear protein Family A G	0.10	72 / 0
C-C chemokine receptor type 5	CCR5	P51681	CHE MBL2 74	protein- coupled receptor Family A G	0.10	0 / 1
Prostanoid EP1 receptor	PTGER1	P34995	CHE MBL1 811	protein- coupled receptor	0.10	264 / 7
Androgen Receptor	AR	P10275	CHE MBL1 871	Nuclear receptor	0.10	3 / 92
Mineralocorticoid receptor	NR3C2	P08235	CHE MBL1 994	Nuclear receptor	0.10	2 / 26
Transient receptor potential cation channel subfamily M member 8	TRPM8	Q7Z2W7	CHE MBL1 07531 9	Voltage- gated ion channel	0.10	24 / 0
Cytochrome P450 26B1	CYP26B1	Q9NR63	CHE MBL3 71368 7	Cytochrome P450 Family A G	0.10	7 / 0
Oxoeicosanoid receptor 1	OXER1	Q8TDS5	CHE MBL1 62846 1	protein- coupled receptor Family A G	0.10	4 / 0
Angiotensin II receptor	AGTR2	P50052	CHE MBL4 607	protein- coupled receptor	0.10	4 / 0
Carboxylesterase 2	CES2	O00748	CHE MBL3 180	Enzyme	0.10	0 / 14
Prolyl endopeptidase	PREP	P48147	CHE MBL3 202	Protease	0.10	0 / 2
Aldose reductase	AKR1B1	P15121	CHE MBL1 900	Enzyme	0.10	102 / 0
Endothelin-converting enzyme 1	ECE1	P42892	CHE MBL4 791	Protease	0.10	32 / 0
Chymase	CMA1	P23946	CHE MBL4 068	Protease	0.10	43 / 0
Cathepsin G	CTSG	P08311	CHE MBL4 071	Protease Family A G	0.10	8 / 0
Endothelin receptor ET-A (by homology)	EDNRA	P25101	CHE MBL2 52	protein- coupled receptor	0.10	46 / 0
Nuclear receptor ROR- alpha	RORA	P35398	CHE MBL5 868	Nuclear receptor	0.10	0 / 4

Fatty acid binding protein epidermal	FABP5	Q01469	CHE MBL3 674 CHE MBL2 61	Fatty acid binding protein family Lyase	0.10	8 / 1
Carbonic anhydrase I	CA1	P00915			0.10	9 / 0